Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/13/2025

Role of Vildagliptin in Type 2 Diabetes Management

Position in Treatment Algorithm

  • Metformin remains the first-line medication for management of type 2 diabetes due to its high efficacy, low cost, minimal hypoglycemia risk, and potential for weight loss, as recommended by the American Diabetes Association 1
  • Vildagliptin is indicated for use in combination therapy when glycemic targets cannot be maintained with metformin monotherapy, according to the American Diabetes Association 2
  • The VERIFY trial demonstrated that initial combination of vildagliptin and metformin provided a lower rate of secondary failure of glycemic control compared to metformin alone or sequential addition, as reported by the American Diabetes Association 4
  • DPP-4 inhibitors like vildagliptin have moderate glucose-lowering efficacy with minimal risk of hypoglycemia when used as monotherapy, as stated by the American Diabetes Association 1

Limitations and Considerations

  • DPP-4 inhibitors like vildagliptin have no evidence of cardiovascular benefit, unlike SGLT2 inhibitors or GLP-1 receptor agonists, according to the American Heart Association 5
  • Current guidelines prioritize SGLT2 inhibitors in patients with heart failure or chronic kidney disease, and GLP-1 receptor agonists in patients with established cardiovascular disease or for weight loss, as recommended by the American College of Cardiology 6
  • The risk-benefit balance for most DPP-4 inhibitors does not justify their use in patients with heart failure, according to the American Heart Association 5

Current Guideline Recommendations

  • In patients with established cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit are preferred over DPP-4 inhibitors like vildagliptin, as recommended by the American College of Cardiology 6
  • For patients without these comorbidities, DPP-4 inhibitors remain a reasonable second-line option after metformin due to their good tolerability and low hypoglycemia risk, according to the American Diabetes Association 1
  • When adding vildagliptin results in adequate glycemic control, clinicians should consider reducing or discontinuing existing treatment with sulfonylureas or long-acting insulins to minimize hypoglycemia risk, as recommended by the American College of Physicians 6

Practical Implementation

  • Consider vildagliptin as part of a combination therapy approach when metformin alone is insufficient for glycemic control, as recommended by the American Diabetes Association 2
  • Regular monitoring of HbA1c every 3-6 months to assess efficacy is recommended, according to the American Association of Clinical Endocrinologists 9
  • Consider the cost implications, as there are currently no generic DPP-4 inhibitors available, as noted by the American College of Physicians 6